The Indian Patent Office’s Draft Guidelines for Examination of Pharmaceutical Patent Applications (2026) face strong criticism for misquoting statutory provisions and misinterpreting legal standards. Stakeholders call for substantial revision before finalization.
Criticism Mounts Over IPO’s Draft Pharma Patent Guidelines (2026)
The Indian Patent Office (IPO) released the Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, 2026, 15 days ago, prompting immediate backlash from legal and industry stakeholders. The draft has been accused of misquoting provisions of the Patents Act, particularly regarding Sections 3(d), 10, and 14, and misapplying legal standards such as inventive step and enablement.
Critics argue that the guidelines conflate clarity and disclosure requirements under Section 10 with substantive patentability criteria, potentially raising the bar beyond statutory intent. The interpretation of Section 3(d) — particularly with respect to polymorphs and derivatives — is seen as overly restrictive and inconsistent with precedent. There are also concerns that the draft encourages the use of post-filed data to reject applications, contrary to established case law.
One commentator noted,
"The 2026 Draft Guidelines risk disrupting patent prosecution as we know it,"urging the IPO to withdraw and substantially revise the document. With public consultation ongoing, stakeholders are calling for expert committee review and alignment with judicial interpretations. The final version could significantly impact pharmaceutical innovation and enforcement strategies in India, making this a high-stakes policy development for IP practitioners.
Citations
- Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, 2026
